A patient with an ST-segment elevation myocardial infarction is being discharged after successful PCI. What is the most appropriate recommendation for statin therapy?

In the context of a patient discharged after a successful percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI), the recommendation of atorvastatin 80 mg daily aligns with current clinical guidelines emphasizing the importance of high-intensity statin therapy in secondary prevention of cardiovascular events.

Atorvastatin at this dose has been shown to significantly reduce rates of cardiovascular morbidity and mortality in patients with a history of myocardial infarction. The high-intensity statin therapy is particularly beneficial due to its potent LDL-C lowering effects, which is crucial for patients with acute coronary syndrome and high cardiovascular risk. Guidelines recommend high-intensity statin therapy as standard care to improve outcomes after an event like an ST-segment elevation myocardial infarction.

Other statins or doses may not provide the same level of LDL-C reduction or cardiovascular protective effect as atorvastatin at the higher dosage. While rosuvastatin can also be considered a high-intensity statin, the specific dosing here does not represent a high-intensity strategy as effectively as atorvastatin 80 mg. Likewise, pravastatin and fluvastatin have lower potencies and would not be classified as high-intensity, thus falling short of current recommendations that favor more